Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
The treatment of gastroesophageal adenocarcinoma (GEA) has undergone significant transformation as novel targeted and immunotherapies have been developed. In particular, multiple treatment approaches are now available for the management of HER2-positive disease across the treatment continuum for metastatic disease, with new therapeutic options poised to join the therapeutic arsenal.
This podcast summarizes recent advances in the management of advanced, HER2-positive GEA, with a particular focus on emerging treatment options, biomarker testing and principles for managing adverse events, led by Rohit Gosain, MD; and Rahul Gosain, MD.
Target Audience
This educational activity is directed toward US and Global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with GEA and BTC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Understand the unique mechanisms of new and novel treatment approaches, including their implications for overcoming tumor heterogeneity and resistance
- Analyze pivotal trials and discuss how novel HER2-targeted therapies improve outcomes, address resistance mechanisms, and shape future strategies for HER2- positive GEA
Rahul Gosain, MD, MBA
Medical Director of Wilmot Cancer Institute at Webster
Director of Wilmot Cancer Institute Regional Infusion Services
Assistant Professor of Clinical Medicine
Wilmot Cancer Institute - University of Rochester
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
Rohit Gosain, MD
Director of Roswell Park Care Network Southtowns
Assistant Professor of Clinical Medicine
Roswell Park Comprehensive Cancer Center - University at Buffalo
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, Oncology News Central, SignifyMD
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.